Drugs / Dexamthasone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02203526 Background | Aug 2014 → Sep 2026 overdue | primary central nervous system lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03476239 Background | Oct 2017 → Aug 2019 | acute lymphoblastic leukemia | Amgen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexamthasone | “Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)” NCT02203526 ↗ |
| Route | Intravenous | “Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle” NCT03476239 ↗ |